India tightens oversight on GLP-1 drugs, warns against misuse for weight loss

Summary

India’s drug regulator has cautioned against the unsupervised use of GLP-1 drugs such as Semaglutide and Tirzepatide, while stepping up scrutiny of misleading advertisements and unauthorized sales, including unapproved versions, amid rising demand beyond their approved use in diabetes care.

NEW DELHI, April 1, 2026 — India’s drug regulator has stepped up oversight of a fast-growing class of diabetes medicines, cautioning against their misuse for weight loss and warning pharmacies and advertisers to comply with existing rules.

The Central Drugs Standard Control Organization (CDSCO), led by the Drug Controller General of India, has issued recent advisories highlighting the risks of unsupervised use of GLP-1 receptor agonists, including Semaglutide and Tirzepatide.

These medicines are approved in India primarily for the treatment of type 2 diabetes, though some formulations are also indicated for obesity under medical supervision.

Focus on responsible prescribing

Health authorities have not announced a blanket ban or specialist-only restriction, but have emphasized that such drugs should be prescribed only by qualified medical practitioners based on clinical need.

Doctors are being advised to follow established treatment guidelines, particularly when prescribing the medicines for weight management, which requires careful evaluation of risks, including gastrointestinal side effects and other complications.

Crackdown on misleading promotion

Regulators have also increased monitoring of advertisements and social media promotions that portray the drugs as quick weight-loss solutions.

Under India’s consumer protection and drug advertising laws, promotion of prescription medicines to the general public is restricted. The Central Consumer Protection Authority has previously warned influencers and platforms against misleading health claims.

Concerns over unapproved versions

Officials have flagged the circulation of unapproved or “compounded” versions of GLP-1 drugs in some markets. Such products are not evaluated under India’s regulatory framework and may pose safety and quality risks.

Authorities said pharmacies must ensure that only approved formulations sourced through authorized channels are dispensed, in line with existing drug control rules.

Rising global demand

Demand for GLP-1 drugs has surged globally, driven by their effectiveness in blood sugar control and weight management. Medicines such as Ozempic and Wegovy have seen strong uptake in several markets, leading to periodic supply constraints.

Indian regulators said ensuring availability for approved medical use remains a priority.

Why this matters

• Reinforces the need for medically supervised use of GLP-1 therapies
• Highlights regulatory focus on misleading health claims and drug promotion
• Addresses risks linked to unapproved or poor-quality drug formulations
• Reflects global surge in demand for diabetes and weight-management therapies
• Signals tighter enforcement of existing pharmaceutical compliance norms

FAQs

Q1. Are GLP-1 drugs banned for weight loss in India?

No. Some formulations are approved for obesity treatment, but only under medical supervision and prescription.

Q2. Can general physicians prescribe these medicines?

Yes, qualified doctors can prescribe them, but must follow clinical guidelines and approved indications.

Q3. What are “compounded” versions of these drugs?

These are non-standard formulations prepared outside approved manufacturing channels and are not regulated like approved medicines.